As CAR-T launch ramps up in U.S., Novartis eyes markets new to performance-based pricing
admin 5th October 2017 Uncategorised 0Novartis is in the very early days of its Kymriah rollout in the U.S., where it will incorporate pay-for-performance pricing on a costly yet promising therapy. But as the drugmaker looks ahead to global approvals, CEO-to-be Vas Narasimhan has to decide how the company will approach markets with no experience in that payment realm, such as Japan.
More: As CAR-T launch ramps up in U.S., Novartis eyes markets new to performance-based pricing
Source: fierce